The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.
GenScript believes that CustomArray's oligonucleotide synthesis and microarray manufacturing technology will enable it to better serve its customers.
The Silicon Valley startup has launched with a proprietary automation platform, and counts CRISPR researcher Jennifer Doudna among its new investors.
The company emerged from stealth mode this month and traces roots to both rocket maker SpaceX and the shuttered sequencing company Halcyon Molecular.
The acquisition of San Diego-based ValueGene expands IDT's presence in Southern California.
IDT said that the acquisition is expected to expand the customer base for its custom synthetic nucleic acid business across Southeast Asia.
A paper in Nature Biotechnology showed that the guide RNAs increased genome editing efficiency in human primary T cells and hematopoietic stem cells.
The company believes it can make oligonucleotide synthesis faster and cheaper than currently available methods, and plans to launch a platform in the next year.
The firm will be a preferred supplier of synthetic oligonucleotides to Research Councils UK Shared Services Centre Ltd.
The German firm will provide synthetic oligos to the RCUK Shared Services Centre Ltd.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.